Evidence map›Paper›PMID 41915442›Full record

ArticleJCI insight2026

Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity.

Anna J Son, Emmanuel Rapp, Alex Wiezorek, Max G Leung, Ronadip R Banerjee, Thomas H Leung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna J SonDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Emmanuel RappDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alex WiezorekDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Max G LeungDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ronadip R BanerjeeDivision of Endocrinology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.
Thomas H LeungDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Neuroimmune Control of Scarless Skin RegenerationR01AR079483 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LEUNG, THOMAS H. · 2021 to 2025
$1.9M
NIAMS NIH HHS R01 AR079483RRD VA I01 RX002701
6 · The paper itself

Abstract

Stopping and restarting GLP-1 weight-loss drugs in mice made them less effective over time and increased fat gain compared with continuous treatment.

Indexed as

AdiposityDrug ResistanceGlucagon-Like Peptide-1 Receptor AgonistsObesityAnimalsExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsLiraglutideMaleMiceSemaglutideVenomsExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideSemaglutideVenomsClinical practiceEndocrinologyMetabolismObesity

Identifiers

PMID41915442
PMCPMC13232713

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.